This document belongs
to @haider254
Test Bank Pharmacology
A Patient-Centered
Nursing Process
Approach, 11th Edition by
Linda E. McCuistion
1
, This document belongs
to @haider254
Table of Contents
Chapter 01: The Nursing Process and Patient-Centered Care......................................................................... 4
Chapter 02: Drug Development and Ethical Considerations ............................................................................ 9
Chapter 03: Pharmacokinetics and Pharmacodynamics ................................................................................ 17
Chapter 04: Pharmacogenetics ..................................................................................................................... 29
Chapter 05: Complementary and Alternative Therapies................................................................................. 32
Chapter 06: Pediatric Considerations ............................................................................................................ 40
Chapter 07: Geriatric Considerations ............................................................................................................. 46
Chapter 08: Drugs in Substance Use Disorder .............................................................................................. 52
Chapter 09: Safety and Quality...................................................................................................................... 58
Chapter 10: Drug Administration ................................................................................................................... 64
Chapter 11: Drug Calculations....................................................................................................................... 69
Chapter 12: Fluid Volume and Electrolytes .................................................................................................... 75
Chapter 13: Vitamin and Mineral Replacement .............................................................................................. 85
Chapter 14: Nutritional Support ..................................................................................................................... 92
Chapter 15: Adrenergic Agonists and Antagonists ....................................................................................... 100
Chapter 16: Cholinergic Agonists and Antagonists ...................................................................................... 106
Chapter 17: Stimulants ................................................................................................................................ 112
Chapter 18: Depressants............................................................................................................................. 117
Chapter 19: Antiseizure Drugs..................................................................................................................... 123
Chapter 20: Drugs for Parkinsonism and Alzheimer Disease ....................................................................... 130
Chapter 21: Drugs for Neuromuscular Disorders and Muscle Spasms ........................................................ 136
Chapter 22: Antipsychotics and Anxiolytics ................................................................................................. 143
Chapter 23: Antidepressants and Mood Stabilizers ..................................................................................... 150
Chapter 24: Anti-inflammatories .................................................................................................................. 157
Chapter 25: Analgesics ............................................................................................................................... 164
Chapter 26: Penicillins, Other Beta-Lactams, and Cephalosporins .............................................................. 170
Chapter 27: Macrolides, Oxazolidinones, Lincosamides, Glycopeptides, Ketolides,and Lipopeptides.......... 176
Chapter 28: Tetracyclines, Glycylcyclines, Aminoglycosides, and Fluoroquinolones ................................... 179
Chapter 29: Sulfonamides and Nitroimidazoles Antibiotics .......................................................................... 183
Chapter 30: Antituberculars, Antifungals, and Antivirals............................................................................... 188
Chapter 31: Antimalarials, Anthelmintics, and Peptides ............................................................................... 197
Chapter 32: HIV- and AIDS-Related Drugs .................................................................................................. 200
Chapter 33: Transplant Drugs ..................................................................................................................... 204
Chapter 34: Vaccines .................................................................................................................................. 206
Chapter 35: Anticancer Drugs ..................................................................................................................... 211
Chapter 36: Targeted Therapies to Treat Cancer ........................................................................................ 215
Chapter 37: Biologic Response Modifiers .................................................................................................... 219
Chapter 38: Upper Respiratory Disorders .................................................................................................... 224
2
, This document belongs
to @haider254
Chapter 39: Lower Respiratory Disorders .................................................................................................... 229
Chapter 40: Cardiac Glycosides, Antianginals, and Antidysrhythmics .......................................................... 235
Chapter 41: Diuretics................................................................................................................................... 244
Chapter 42: Antihypertensives..................................................................................................................... 249
Chapter 43: Anticoagulants, Antiplatelets, and Thrombolytics...................................................................... 255
Chapter 44: Adult and Pediatric Emergency Drugs ...................................................................................... 264
Chapter 45: Gastrointestinal Tract Disorders ............................................................................................... 269
Chapter 46: Antiulcer Drugs ........................................................................................................................ 276
Chapter 47: Eye and Ear Disorders ............................................................................................................. 283
Chapter 48: Dermatologic Disorders............................................................................................................ 287
Chapter 49: Pituitary, Thyroid, Parathyroid, and Adrenal Disorders ............................................................. 292
Chapter 50: Antidiabetics ............................................................................................................................ 301
Chapter 51: Urinary Disorders ..................................................................................................................... 309
Chapter 52: Pregnancy and Preterm Labor ................................................................................................. 315
Chapter 53: Labor, Delivery, and Postpartum .............................................................................................. 322
Chapter 54: Neonatal and Newborn ............................................................................................................ 328
Chapter 55: Women’s Reproductive Health ................................................................................................. 330
Chapter 56: Men’s Health and Reproductive Disorders ............................................................................... 338
Chapter 57: Sexually Transmitted Infections ............................................................................................... 342
Chapter 58: Antihyperlipidemics and Drugs to Improve Peripheral Blood Flow ............................................ 345
3
, This document belongs
to @haider254
Chapter 01: The Nursing Process and Patient-Centered Care
MULTIPLE CHOICE
1. All of the following would be considered subjective data, EXCEPT:
a. Patient-reported health history
b. Patient-reported signs and symptoms of their illness
c. Financial barriers were reported by the patient’s caregiver.
d. Vital signs obtained from the medical record.
ANS: D.
D.
Subjective data is based on what patients or family members communicate to the nurse.
Patient-reported health history, signs and symptoms, and caregiver reportedfinancial
barriers would be considered subjective data. Vital signs obtained from themedical record
would be considered objective data.
DIF: Cognitive Level: Understanding (Comprehension) TOP: Nursing Process:
PlanningMSC: NCLEX: Management of Client Care
2. The nurse is using data collected to define a set of interventions to achieve the mostdesirable
outcomes. Which of the following steps is the nurse applying?
a. Recognizing cues (assessment)
b. Analyze cues & prioritize hypothesis (analysis)
c. Generate solutions (planning)
d. Take action (nursing interventions)
ANS: C
C
When generating solutions (planning), the nurse identifies expected outcomes and usesthe
patient’s problem(s) to define a set of interventions to achieve the most desirable outcomes.
Recognizing cues (assessment) involves the gathering of cues (information) from the patient
about their health and lifestyle practices, which are important facts that aid the nurse in making
clinical care decisions. Prioritizing hypothesis is used to organize and rank the patient
problem(s)identified. Finally, taking action involves implementation of nursing interventions to
accomplish the expected outcomes.
DIF: Cognitive Level: Understanding
(Comprehension)TOP: Nursing Process: Nursing
Intervention
MSC: NCLEX: Management of Client Care
3. A 5-year-old child with type 1 diabetes mellitus has had repeated hospitalizations for episodes
of hyperglycemia. The parents tell the nurse that they can’t keep track of everything that has to
be done to care for their child. The nurse reviews medications, diet, and symptom management
with the parents and draws up a daily checklist for thefamily to use. These activities are
completed in which step of the nursing process?
a. Recognizing cues (assessment)
b. Analyze cues & prioritize hypothesis (analysis)
c. Generate solutions (planning)
d. Take action (nursing interventions)
4
to @haider254
Test Bank Pharmacology
A Patient-Centered
Nursing Process
Approach, 11th Edition by
Linda E. McCuistion
1
, This document belongs
to @haider254
Table of Contents
Chapter 01: The Nursing Process and Patient-Centered Care......................................................................... 4
Chapter 02: Drug Development and Ethical Considerations ............................................................................ 9
Chapter 03: Pharmacokinetics and Pharmacodynamics ................................................................................ 17
Chapter 04: Pharmacogenetics ..................................................................................................................... 29
Chapter 05: Complementary and Alternative Therapies................................................................................. 32
Chapter 06: Pediatric Considerations ............................................................................................................ 40
Chapter 07: Geriatric Considerations ............................................................................................................. 46
Chapter 08: Drugs in Substance Use Disorder .............................................................................................. 52
Chapter 09: Safety and Quality...................................................................................................................... 58
Chapter 10: Drug Administration ................................................................................................................... 64
Chapter 11: Drug Calculations....................................................................................................................... 69
Chapter 12: Fluid Volume and Electrolytes .................................................................................................... 75
Chapter 13: Vitamin and Mineral Replacement .............................................................................................. 85
Chapter 14: Nutritional Support ..................................................................................................................... 92
Chapter 15: Adrenergic Agonists and Antagonists ....................................................................................... 100
Chapter 16: Cholinergic Agonists and Antagonists ...................................................................................... 106
Chapter 17: Stimulants ................................................................................................................................ 112
Chapter 18: Depressants............................................................................................................................. 117
Chapter 19: Antiseizure Drugs..................................................................................................................... 123
Chapter 20: Drugs for Parkinsonism and Alzheimer Disease ....................................................................... 130
Chapter 21: Drugs for Neuromuscular Disorders and Muscle Spasms ........................................................ 136
Chapter 22: Antipsychotics and Anxiolytics ................................................................................................. 143
Chapter 23: Antidepressants and Mood Stabilizers ..................................................................................... 150
Chapter 24: Anti-inflammatories .................................................................................................................. 157
Chapter 25: Analgesics ............................................................................................................................... 164
Chapter 26: Penicillins, Other Beta-Lactams, and Cephalosporins .............................................................. 170
Chapter 27: Macrolides, Oxazolidinones, Lincosamides, Glycopeptides, Ketolides,and Lipopeptides.......... 176
Chapter 28: Tetracyclines, Glycylcyclines, Aminoglycosides, and Fluoroquinolones ................................... 179
Chapter 29: Sulfonamides and Nitroimidazoles Antibiotics .......................................................................... 183
Chapter 30: Antituberculars, Antifungals, and Antivirals............................................................................... 188
Chapter 31: Antimalarials, Anthelmintics, and Peptides ............................................................................... 197
Chapter 32: HIV- and AIDS-Related Drugs .................................................................................................. 200
Chapter 33: Transplant Drugs ..................................................................................................................... 204
Chapter 34: Vaccines .................................................................................................................................. 206
Chapter 35: Anticancer Drugs ..................................................................................................................... 211
Chapter 36: Targeted Therapies to Treat Cancer ........................................................................................ 215
Chapter 37: Biologic Response Modifiers .................................................................................................... 219
Chapter 38: Upper Respiratory Disorders .................................................................................................... 224
2
, This document belongs
to @haider254
Chapter 39: Lower Respiratory Disorders .................................................................................................... 229
Chapter 40: Cardiac Glycosides, Antianginals, and Antidysrhythmics .......................................................... 235
Chapter 41: Diuretics................................................................................................................................... 244
Chapter 42: Antihypertensives..................................................................................................................... 249
Chapter 43: Anticoagulants, Antiplatelets, and Thrombolytics...................................................................... 255
Chapter 44: Adult and Pediatric Emergency Drugs ...................................................................................... 264
Chapter 45: Gastrointestinal Tract Disorders ............................................................................................... 269
Chapter 46: Antiulcer Drugs ........................................................................................................................ 276
Chapter 47: Eye and Ear Disorders ............................................................................................................. 283
Chapter 48: Dermatologic Disorders............................................................................................................ 287
Chapter 49: Pituitary, Thyroid, Parathyroid, and Adrenal Disorders ............................................................. 292
Chapter 50: Antidiabetics ............................................................................................................................ 301
Chapter 51: Urinary Disorders ..................................................................................................................... 309
Chapter 52: Pregnancy and Preterm Labor ................................................................................................. 315
Chapter 53: Labor, Delivery, and Postpartum .............................................................................................. 322
Chapter 54: Neonatal and Newborn ............................................................................................................ 328
Chapter 55: Women’s Reproductive Health ................................................................................................. 330
Chapter 56: Men’s Health and Reproductive Disorders ............................................................................... 338
Chapter 57: Sexually Transmitted Infections ............................................................................................... 342
Chapter 58: Antihyperlipidemics and Drugs to Improve Peripheral Blood Flow ............................................ 345
3
, This document belongs
to @haider254
Chapter 01: The Nursing Process and Patient-Centered Care
MULTIPLE CHOICE
1. All of the following would be considered subjective data, EXCEPT:
a. Patient-reported health history
b. Patient-reported signs and symptoms of their illness
c. Financial barriers were reported by the patient’s caregiver.
d. Vital signs obtained from the medical record.
ANS: D.
D.
Subjective data is based on what patients or family members communicate to the nurse.
Patient-reported health history, signs and symptoms, and caregiver reportedfinancial
barriers would be considered subjective data. Vital signs obtained from themedical record
would be considered objective data.
DIF: Cognitive Level: Understanding (Comprehension) TOP: Nursing Process:
PlanningMSC: NCLEX: Management of Client Care
2. The nurse is using data collected to define a set of interventions to achieve the mostdesirable
outcomes. Which of the following steps is the nurse applying?
a. Recognizing cues (assessment)
b. Analyze cues & prioritize hypothesis (analysis)
c. Generate solutions (planning)
d. Take action (nursing interventions)
ANS: C
C
When generating solutions (planning), the nurse identifies expected outcomes and usesthe
patient’s problem(s) to define a set of interventions to achieve the most desirable outcomes.
Recognizing cues (assessment) involves the gathering of cues (information) from the patient
about their health and lifestyle practices, which are important facts that aid the nurse in making
clinical care decisions. Prioritizing hypothesis is used to organize and rank the patient
problem(s)identified. Finally, taking action involves implementation of nursing interventions to
accomplish the expected outcomes.
DIF: Cognitive Level: Understanding
(Comprehension)TOP: Nursing Process: Nursing
Intervention
MSC: NCLEX: Management of Client Care
3. A 5-year-old child with type 1 diabetes mellitus has had repeated hospitalizations for episodes
of hyperglycemia. The parents tell the nurse that they can’t keep track of everything that has to
be done to care for their child. The nurse reviews medications, diet, and symptom management
with the parents and draws up a daily checklist for thefamily to use. These activities are
completed in which step of the nursing process?
a. Recognizing cues (assessment)
b. Analyze cues & prioritize hypothesis (analysis)
c. Generate solutions (planning)
d. Take action (nursing interventions)
4
